Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the effect of the human homolog of the Kirsten rat
sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue
on efficacy endpoints in patients with metastatic colorectal cancer (mCRC) receiving
second-line chemotherapy with panitumumab after failing first-line treatment.